New Concentrated Humalog Pen Approved by the FDA

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

A new strength of Humalog has been approved by the FDA: the Humalog U-200 KwikPen will offer another form of rapid-acting insulin to improve sugar control in adults with type 1 and type 2 diabetes.

What is rapid-acting insulin?

Rapid-acting insulin lowers blood sugar levels quickly; once injected it can take effect within 15 minutes and can last anywhere from three to five hours, continuing to lower your blood sugar after a meal.

Are there other rapid-acting insulins available?

Yes. Other examples of rapid-acting insulin include:

Is the Humalog U-200 KwikPen similar to any of the other rapid-acting insulins?

Yes. The Humalog U-200 KwikPen has the same active ingredient, insulin lispro, as the existing Humalog 100 units/mL vial, cartridge, and KwikPen.

How is the new Humalog U-200 different?

Although the Humalog U-200 KwikPen has the same active ingredient as Humalog 100 units/mL, the difference is in the strength. Humalog U-200 KwikPen has 200 units/mL, while the other Humalog pens and vials have 100 units/mL.

How will Humalog U-200 KwikPen be available?
Humalog U-200 KwikPen will be available as a disposable pre-filled 200 units/mL KwikPen.

How will Humalog U-200 be used?

The u-200 KwikPen is to be administered subcutaneously within 15 minutes before eating or right after eating a meal.

What are common side effects of Humalog?

The most common side effect associated with Humalog is hypoglycemia.

Is there anything unique about this FDA approval?

Yes. The Humalog U-200 KwikPen is the first FDA approval of a concentrated mealtime insulin. This medication has twice the amount of insulin lispro compared to the other Humalog 100 unit/mL formulations.

Is there an advantage to using Humalog 200 units/mL compared to Humalog 100 units/mL?

Yes. Some advantages include:

Drugs featured in this story

Filed under